Emerging and Evolving Biomarkers: ERBB2 (HER2)




Speaker:
Sinchita Roy-Chowdhuri, MD, PhD
Moderator:
Anthony Snow, MD

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and audience Q&A

Description:

The human epidermal growth factor receptor 2 gene ERBB2 (HER2) is amplified in many cancer types. Overexpression of ERBB2 has been used successfully as a therapeutic target in breast and gastric cancers with a variety of anti-ERBB2 agents. In contrast, the role of ERBB2 in colorectal cancer is not as well established. Molecular characterization of colorectal cancer has identified ERBB2 amplification as a potential therapeutic target and activation of ERBB2 signaling causes resistance to anti-EGFR therapy in a subset of patients with metastatic colorectal cancer. The biology and clinicopathologic correlations of ERBB2 amplification in colorectal cancer, as well as testing strategies to optimize detection of this alteration in clinical practice, will be addressed in this presentation.

Learning Objectives:

  • Describe the biological principles that underlie the role of ERBB2 amplification in cancer, with a focus on its role in colorectal cancer
  • Discuss the appropriate technical approaches and platforms for testing for ERBB2 amplification
  • Outline the strengths and limitations of described testing approaches
  • Discuss interpretation of biomarker status results within a clinical context

This webinar is part 5 of the Emerging and Evolving Biomarkers Series

Supported by an educational grant from Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com), which had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.

Recording Date: April 15, 2021
Duration: 1 Hour
Level of Instruction: Basic
CME/CMLE Credit: 1.0 
Last day to claim credit: December 31, 2022

How to claim credit: 

To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.


AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation